Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 10770.0
(0.19%)
KRW 10770.0
(0.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -14.49 Billion KRW | 8.27% |
| 2022 | -15.8 Billion KRW | 21.17% |
| 2021 | -20.05 Billion KRW | -142.75% |
| 2020 | -8.25 Billion KRW | -1176.61% |
| 2019 | 767.21 Million KRW | -70.69% |
| 2018 | 2.61 Billion KRW | 114.9% |
| 2017 | 1.21 Billion KRW | 115.09% |
| 2016 | -8.07 Billion KRW | -1234.6% |
| 2015 | 711.28 Million KRW | 153.75% |
| 2014 | -1.32 Billion KRW | 86.07% |
| 2013 | -9.49 Billion KRW | -19.37% |
| 2012 | -7.95 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.18 Billion KRW | 114.66% |
| 2024 Q2 | 2.3 Billion KRW | 94.63% |
| 2023 Q3 | -1.97 Billion KRW | 15.32% |
| 2023 Q1 | -2.09 Billion KRW | 81.19% |
| 2023 FY | -14.49 Billion KRW | 8.27% |
| 2023 Q4 | -8.08 Billion KRW | -308.58% |
| 2023 Q2 | -2.33 Billion KRW | -11.47% |
| 2022 FY | -15.8 Billion KRW | 21.17% |
| 2022 Q4 | -11.14 Billion KRW | -432.15% |
| 2022 Q1 | -2.13 Billion KRW | 84.2% |
| 2022 Q2 | -5.88 Billion KRW | -175.6% |
| 2022 Q3 | 3.35 Billion KRW | 157.04% |
| 2021 Q1 | -2.01 Billion KRW | 69.37% |
| 2021 Q4 | -13.51 Billion KRW | -421.36% |
| 2021 FY | -20.05 Billion KRW | -142.75% |
| 2021 Q2 | -1.93 Billion KRW | 4.14% |
| 2021 Q3 | -2.59 Billion KRW | -34.2% |
| 2020 Q1 | -1.17 Billion KRW | -13549.43% |
| 2020 Q3 | -321.9 Million KRW | -77.82% |
| 2020 Q4 | -6.57 Billion KRW | -1943.3% |
| 2020 FY | -8.25 Billion KRW | -1176.61% |
| 2020 Q2 | -181.02 Million KRW | 84.65% |
| 2019 Q4 | -8.64 Million KRW | -101.07% |
| 2019 Q3 | 810.37 Million KRW | 164.1% |
| 2019 Q2 | 306.84 Million KRW | -33.36% |
| 2019 Q1 | 460.48 Million KRW | -81.86% |
| 2019 FY | 767.21 Million KRW | -70.69% |
| 2018 FY | 2.61 Billion KRW | 114.9% |
| 2018 Q3 | 732.95 Million KRW | 493.4% |
| 2018 Q2 | 123.51 Million KRW | 143.13% |
| 2018 Q1 | -286.37 Million KRW | -117.48% |
| 2018 Q4 | 2.53 Billion KRW | 246.3% |
| 2017 Q3 | 624.59 Million KRW | 822.04% |
| 2017 FY | 1.21 Billion KRW | 115.09% |
| 2017 Q2 | 67.74 Million KRW | 106.09% |
| 2017 Q1 | -1.11 Billion KRW | 80.9% |
| 2017 Q4 | 1.63 Billion KRW | 162.31% |
| 2016 Q3 | -2.12 Billion KRW | -688.5% |
| 2016 Q4 | -5.82 Billion KRW | -174.31% |
| 2016 FY | -8.07 Billion KRW | -1234.6% |
| 2016 Q1 | 146.24 Million KRW | 121.25% |
| 2016 Q2 | -269.26 Million KRW | -284.12% |
| 2015 Q3 | 942.54 Million KRW | 223.66% |
| 2015 Q1 | 165.73 Million KRW | 205.1% |
| 2015 FY | 711.28 Million KRW | 153.75% |
| 2015 Q4 | -688.2 Million KRW | -173.02% |
| 2015 Q2 | 291.21 Million KRW | 75.7% |
| 2014 Q3 | 201.9 Million KRW | 124.52% |
| 2014 Q1 | -544.22 Million KRW | 83.67% |
| 2014 FY | -1.32 Billion KRW | 86.07% |
| 2014 Q4 | -157.69 Million KRW | -178.1% |
| 2014 Q2 | -823.32 Million KRW | -51.28% |
| 2013 Q2 | -2.58 Billion KRW | -67.78% |
| 2013 Q4 | -3.33 Billion KRW | -63.8% |
| 2013 Q3 | -2.03 Billion KRW | 21.4% |
| 2013 FY | -9.49 Billion KRW | -19.37% |
| 2013 Q1 | -1.54 Billion KRW | -219.14% |
| 2012 Q4 | -483.44 Million KRW | 0.0% |
| 2012 FY | -7.95 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | -10.38 Billion KRW | -39.649% |
| ST Pharm Co.,Ltd. | 19.58 Billion KRW | 174.047% |
| ABL Bio Inc. | -2.64 Billion KRW | -447.835% |
| Cellid, Co., Ltd. | -11.61 Billion KRW | -24.871% |